Insider trade

Director received an award of 231 IDXX derivative securities

Traded Dec 1, 2025 · Filed Dec 3, 2025

Idexx LaboratoriesIDXX

231
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Dec 1, 2025
Reporting period: Not applicable
Filed with the SEC: Dec 3, 2025

DirectorGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

None found in footnotes

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000874716-25-000170
Filed / recorded

Dec 3, 2025, 10:01 PM UTC

Added to OQRO

Oct 2, 2026, 12:28 PM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

IDEXX LABORATORIES INC /DE

Issuer CIK

874716

Ticker

IDXX

Reporting person

Karen Peacock

Relationship

Director

Security

Non-Qualified Stock Option (right-to-buy)

Table

Derivative (Table II)

Transaction date

Dec 1, 2025

Transaction code

A

Shares / units

231

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

231

Ownership form

Direct

Amendment

No

Footnotes from the filing

This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from the date of her election to the IDEXX Laboratories, Inc. Board of Directors on October 6, 2025 until the 2026 annual meeting of stockholders.
Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 7, 2026 or on the date of the 2026 annual meeting of stockholders, whichever event is earlier.